FibroBiologics, Inc. (FBLG)
| Market Cap | 4.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.68M |
| Shares Out | 5.40M |
| EPS (ttm) | -6.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,350 |
| Open | 0.798 |
| Previous Close | 0.826 |
| Day's Range | 0.786 - 0.820 |
| 52-Week Range | 0.731 - 15.000 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 13.50 (+1,546.34%) |
| Earnings Date | Jul 30, 2026 |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, includi... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FBLG stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 1,546.34% from the latest price.
News
FibroBiologics announces $9M private placement priced at-the-market
FibroBiologics (FBLG) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,081,633 shares of common stock, series A warrants to purchase up…
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants HOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NAS...
FibroBiologics Transcript: AGM 2026
The meeting covered board changes, approved all four shareholder proposals, and addressed concerns about Nasdaq listing compliance and the impact of potential delisting. Voting results will be reported to the SEC within four business days.
FibroBiologics receives notice of allowance for U.S. patent
FibroBiologics (FBLG) announced that the United States Patent and Trademark Office, or USPTO, has issued a notice of allowance for the company’s patent application entitled “Therapeutic Use of Fibrobl...
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers Allowed claims directly support the Company's ongoing Phase 1/2 clinical...
FibroBiologics doses first patients in CYWC628 clinical trial
FibroBiologics (FBLG) announced that the first patients have been dosed in the company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers. Initial dosing took plac...
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the devel...
FibroBiologics doses first patients in CYWC628 trial
FibroBiologics (FBLG) announced that the first patients have been enrolled and dosed in the company’s Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers. Published f...
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the devel...
FibroBiologics presents preclinical data from CYPS317 program
FibroBiologics (FBLG) announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Il...
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease In animal studies, human...
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
HOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development...
FibroBiologics expands fibroblast-based platform to target Hantavirus
FibroBiologics (FBLG) announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome, the ...
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated...
FibroBiologics CEO Issues Letter to Shareholders
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics Proxy statement: Proxy filing
FibroBiologics filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring
FibroBiologics (FBLG) announced preclinical results suggesting that topical treatment with human dermal fibroblast spheroids may reprogram the burn wound environment by dampening harmful inflammation,...
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial
FibroBiologics (FBLG) announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers. “With the first…
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the develo...
FibroBiologics downgraded to Hold from Buy at Maxim
Maxim analyst Michael Okunewitch downgraded FibroBiologics (FBLG) to Hold from Buy.
FibroBiologics reports Q1 net loss roughly ($5M)
The net loss for the three months ended March 31, 2026, was primarily due to research and development expenses and general and administrative expenses. Pete O’Heeron, CEO, and Founder of…
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in...
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the deve...